Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Equillium, Inc. EQ

8 fiscal years on record · USD · FY2025 reported · SEC filings only
$-22.4M
$-22.8M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

EQ302 is a preclinical-stage, first-in-class, selective, bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery. As of December 31, 2025, the company employed 14 employees, of which 13 were full-time employees, who were engaged in research and development activities, operations, finance, business development or administration. The company was originally incorporated as Attenuate Biopharmaceuticals, Inc. in Delaware in March 2017 and subsequently changed its name to Equillium, Inc. in May 2017. The company has three wholly-owned subsidiaries, Bioniz Therapeutics, Inc., a Delaware corporation, Ariagen, Inc., a Delaware corporation, and Equillium Australia Pty LTD, an Australian proprietary limited corporation.

Written from the business description in Equillium, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 25 March 2026. Every sentence was checked against that document before publication.

Growth

·
Revenue, FY2025 · full 8-year series below
Revenue $M Net income $M
FY2024 · Revenue 41.1 · Net income -8.1
15.0M30.0M-25.0M-50.0M
2018202120242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2024 · Operating -20.1% · Net -19.6%
-100%-200%-300%
201820212025
ROE
FY2025 · ROE -94.0%
-50%-100%
201820212025
Three returns, three denominators.

Each USD of equity lost 94 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -22.8
-15M-30M
201820212025
Net buybacks $ Dividends $
FY2023 · Dividends · · Net buybacks 260000.0
100000200000
2023

Total assetsUSD 31.9M
EquityUSD 28.6M
CashUSD 30.3M
Current ratio10.58×

Equity funds 90% of total assets.

The 8-year record

8 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
EQ, 8-year financial record
Metric 20252024202320222021202020192018
Revenue $B◌0.00.00.0◌◌◌◌
Operating income $B−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.0◌◌
Net income $B−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.39−0.23−0.38−1.85−1.36−1.46−1.47−1.09
Dividend / sh $◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————
ROE %−94.0−38.8−48.9−126.8−57.3−53.4−47.9—
Shares out B0.060.040.040.030.030.020.020.02

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 35 reconciliationsAUDITED

Reconciled in 8 of the 8 fiscal years we could check. 20 checks were skipped: the balance sheet is not tagged before 2017. 11 checks were skipped: EPS is not tagged before 2018.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2017

Share this section

Download image